FDA Lifts Simufilam Hold, Clearing Filana’s Phase 2a Study

Key Facts

Filana Therapeutics said the FDA lifted the clinical hold on simufilam’s investigational new drug application, allowing the company to initiate its planned Phase 2a study in patients with tuberous sclerosis complex-related epilepsy. Patient screening is expected to begin by the first quarter of 2027.

The 16-week multicenter, randomized, double-blind study will evaluate 2 simufilam doses in 40 participants aged 12 to 55 across 13 sites in the United States. Participants who complete the double-blind treatment phase will be eligible for a 48-week extension study.

Simufilam is an oral small molecule intended to modulate the filamin A protein. The scientific rationale presented by the company rests on preclinical mouse models, while the Phase 2a study will assess safety, tolerability, pharmacokinetics and seizure measures; lifting the hold therefore neither establishes efficacy nor constitutes marketing approval.

For investors, the decision removes a regulatory barrier that had prevented the study from starting, but shifts the focus of risk to trial execution, enrollment, and subsequent safety, tolerability and seizure data. Because the decision authorizes clinical research rather than marketing, it does not establish simufilam’s clinical or commercial viability.